Esker to Automate Juniper Biologics Accounts Payable Processes

Singapore — 19 April, 2022 Esker, a global cloud platform and leader in AI-driven process automation solutions for finance and customer service functions, today announced that Juniper Biologics,a science-led healthcare company focused on Researching, Developing and Commercialising novel therapies, has selected Esker to automate its accounts payable (AP) processes.  

With Esker, Juniper Biologics intends to digitally transform its AP operations into a highly collaborative, efficient and visible process. Eliminating manual tasks and processing invoices on a single platform, Esker's Accounts Payable solution will support Juniper Biologics in improving operational efficiency by giving employees and suppliers the visibility and information they need to speed up the AP process.

"We are continually investing in our business processes to scale alongside our growing needs and to allow our people to focus on more strategic activities that impact cash management and improve supplier relationships," said Raman Singh, CEO at Juniper Biologics. "AI-powered intelligence and technology are vital for driving business insights and increasing innovation, and Esker is the perfect fit for Juniper Biologics as we continue our automation journey."

"In a fast-changing and challenging business environment, accelerating the adoption of advanced technologies that improve the workplace and retain talent is highly critical,” said Albert Leong, Managing Director at Esker Asia. “By reducing mundane and repetitive manual tasks in core finance processes, businesses can provide a collaborative environment for all internal and external stakeholders, thereby promoting positive-sum growth. We are very happy to be partnering with Juniper Biologics in their digital transformation initiative." 

About Juniper Biologics

Backed by The Sylvan Group, Juniper Biologics is a science-led healthcare company focused on delivering novel therapies to improve the health and quality of life of patients, by building a growing presence in Oncology, Rare/Orphan Diseases and Gene Therapy. It was founded on a vision to provide treatments for unmet medical needs focused on specialist therapy areas in which it can make the most difference. Through bold and transformative science, Juniper Biologics is committed to creating possibilities that have the potential to become the next generation of life-changing medicines for patient communities in China, Japan, Asia, Australia, New Zealand, Middle East and Africa. Learn more: https://www.juniperbiologics.com/

About Esker

Esker is a global cloud platform built to unlock strategic value for finance and customer service professionals, and strengthen collaboration between companies by automating the cash conversion cycle. Esker’s solutions incorporate technologies like Artificial Intelligence (AI) to drive increased productivity, enhanced visibility, reduced fraud risk, and improved collaboration with customers, suppliers and internally. Esker operates in North America, Latin America, Europe and Asia Pacific with global headquarters in Lyon, France, and U.S. headquarters in Madison, Wisconsin. For more information on Esker and its solutions, visit www.esker.com.sg. Follow Esker on LinkedIn @EskerAsia and join the conversation on the Esker blog at blog.esker.com.sg

https://www.esker.com.sg/sites/default/files/press_releases/esker_juniper_biologics_pr_19_april_002.pdf

Top